In brief
Britain’s health watchdog announced a study that will analyze blood and urine from the Health Survey for England to quantify exposure to PFAS, lead and arsenic, with preliminary data slated for 2027. Chief scientist Dr Edward Wynne‑Evans notes limited evidence of health effects but cites possible links to raised cholesterol and lower birth weight, underscoring the need for further investigation.
On Tuesday, Nov. 3, 2026, the UK Health Security Agency (UKHSA) announced a comprehensive study to assess the public’s exposure to per‑ and polyfluoroalkyl substances (PFAS), commonly called “forever chemicals,” as well as heavy metals such as lead and arsenic. The study will draw on blood and urine samples collected through the existing Health Survey for England, aiming to produce preliminary findings by 2027.
The Health Survey for England provides a regularly collected, nationally representative set of biological specimens. By analyzing these samples for PFAS, lead, arsenic and other chemicals, UKHSA intends to map contaminant levels across the population and examine associations with health outcomes.
Scope and Methodology
UKHSA will quantify concentrations of multiple PFAS compounds in samples, alongside measurements of lead, arsenic and other potentially toxic agents. The approach involves laboratory analysis of existing biological specimens without the need for new blood draws, enabling immediate access to a large dataset.
Dr Edward Wynne‑Evans, director of radiation, chemicals, climate and environmental hazards at UKHSA, said significant gaps remain in understanding what different levels of PFAS exposure mean for an individual’s long‑term health.
The evidence available to date suggests that any health effects are likely to be limited,
he added. “The strongest evidence currently points to possible associations with raised cholesterol and lower birth weight,” Dr Wynne‑Evans said. Those links were the most frequently cited in existing studies, though the agency noted that the overall evidence base remains sparse.
UKHSA has not yet recommended routine blood testing for PFAS. In the absence of conclusive evidence on what medical action should follow a particular result, the agency is awaiting further data before issuing guidelines for clinical practice.
The agency is also collaborating with international partners to monitor emerging evidence and assess potential health risks. These joint efforts aim to bring together data from other national surveys and laboratory studies to strengthen the overall understanding of PFAS exposure worldwide.
Preliminary results from the study are expected in 2027, with more detailed findings anticipated for 2028. The timeline reflects the time necessary for laboratory analysis, data processing and robust peer review before public dissemination.
While the study will clarify how widespread PFAS exposure is in Britain, several uncertainties remain. The evidence base points to limited health effects, but associations with raised cholesterol and lower birth weight require confirmation in larger, longitudinal studies. Consequently, the long‑term health implications of the levels of PFAS detected, and the significance of these associations, are still unresolved, a point the agency has emphasized throughout its announcement. The study’s outcomes will address only some of these gaps, leaving broader questions about exposure thresholds and risk thresholds open for future research.
